The Effects of L-arabinose on Intestinal Sucrase Activity in Man

This study has been completed.
Sponsor:
Collaborator:
Danisco
Information provided by (Responsible Party):
Jens Rikardt Andersen, University of Copenhagen
ClinicalTrials.gov Identifier:
NCT00302302
First received: September 21, 2005
Last updated: February 25, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to investigate the effect of L-arabinose in a sugar-rich meal on intestinal sucrase activity in healthy volunteers by measuring postprandial blood glucose and insulin, and selected intestinal hormonal responses to increasing doses of L-arabinose.


Condition Intervention Phase
Blood Glucose
Drug: L-arabinose
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Prevention
Official Title: The Effects of Increasing Doses of L-arabinose in a Sucrose Rich Meal on Intestinal Sucrase Activity in Man

Resource links provided by NLM:


Further study details as provided by University of Copenhagen:

Primary Outcome Measures:
  • Plasma glucose, insulin, triglycerides, GIP and GLP-1 [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
    Blood samples 2 hours after a test meal


Secondary Outcome Measures:
  • Appetite measurements and energy intake [ Time Frame: 10 hours ] [ Designated as safety issue: No ]
    measured after a test meal


Enrollment: 15
Study Start Date: September 2005
Study Completion Date: January 2006
Primary Completion Date: November 2005 (Final data collection date for primary outcome measure)
Detailed Description:

Background:

The intake of common table sugar (sucrose) in the industrialised countries is relatively high. In Denmark the daily intake of sugar is in the range of 30-40 g/d exclusive the intake of sugar containing drinks. The health consequences of this relatively high sugar intake are heavily debated in the media. One of the arguments is that a high sugar intake may be one of the factors involved in the development of the metabolic syndrome, including overweight, increased blood glucose and insulin levels as well as impaired insulin action.

L-arabinose is widely distributed in plants and is a common component in plant cell walls in maize, wheat, rye, rice, plant gums etc. The isolated 5-carbon sugar has been shown to suppress the increase of blood glucose and plasma insulin after ingestion of sucrose in rats by inhibition of sucrase activity. In vitro studies on Caco-2 cells indicate that L-arabinose is a potent inhibitor on sucrase activity, possibly in a non-competitive way.

Potential nutritional advantages of consuming L-arabinose in combination with sucrose may therefore be a delayed digestion of sucrose and a lower absorption of glucose, resulting in both lower blood glucose and insulin levels. A delayed digestion of sucrose will reduce the energy utilisation with the potential of reducing weight gain in human subjects.

Methods:

This dose-response study with 14 healthy male volunteers has a randomised cross-over design based on four single "meals" separated by one week wash-out periods. Sugar rich drinks supplemented with different doses of L-arabinose will be tested with respect to postprandial blood glucose, insulin, triglyceride, glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). Postprandial blood samples will be taken every 15 to 30 min for 180 min. Appetite sensations will be measured every 30 min during the experiment. After 180 minutes a lunch will be served and energy intake (EI) will be registered.

  Eligibility

Ages Eligible for Study:   18 Years to 30 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy males
  • BMI between 18.4-25 kg/m2
  • age between 18 and 30

Exclusion Criteria:

  • donation of blood 3 months before or during the study
  • gastrointestinal disorders, diabetes, hypertension, hyperlipidemia, chronic infectious disease (HIV or hepatitis)
  • smoking
  • consumption of more than 21 alcoholic drinks/week
  • elite athletes
  • on medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00302302

Locations
Denmark
Institute of Human Nutrition, The Royal Veterinary and Agricultural University
Frederiksberg, Denmark, DK-1958
Sponsors and Collaborators
University of Copenhagen
Danisco
Investigators
Principal Investigator: Klaus Bukhave, MSc, MScD Institute of Human Nutrition, The Royal Veterinary and Agricultural University, Denmark
  More Information

No publications provided by University of Copenhagen

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jens Rikardt Andersen, Associate Professor, University of Copenhagen
ClinicalTrials.gov Identifier: NCT00302302     History of Changes
Other Study ID Numbers: (KF) 01 270121, M181
Study First Received: September 21, 2005
Last Updated: February 25, 2014
Health Authority: Denmark: The Danish National Committee on Biomedical Research Ethics

Keywords provided by University of Copenhagen:
Blood glucose
Insulin
Triglyceride
GIP
GLP-1
L-arabinose
Appetite
Energy intake

ClinicalTrials.gov processed this record on October 20, 2014